Frontlight ResearchEarly access
Taking peopleNo phase
Acute EpiDural Hematoma Treated With Middle Meningeal Artery Embolization: a Randomized Trial (AEDH-MT)
Key facts
- Who runs it
- Changhai Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 194 people, planned
- Started
- 2 Sept 2024
- Expected to end
- Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- MMA embolization plus medical therapy
- Medical therapy alone
- Record updated
- 4 April 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- Age 18 or above;
- Patients with a clear history of head trauma and confirmed acute epidural hematoma by head CT;
- Cases that the case screening committee deems suitable for conservative treatment*;
- Randomly within 6 hours after injury, and initiate treatment within 8 hours after injury;
- Epidural hematoma located on the convex surface of the brain (frontal, temporal, parietal, or occipital);
- The patient or their representative agrees and signs an informed consent form. * The case screening committee is composed of three senior neurosurgeons, with two of them jointly deciding whether conservative treatment is possible. If there is a disagreement, the third doctor will make the final judgment. Including but not limited to the following two situations: 1. Hematoma volume<30ml, hematoma thickness<15mm, midline shift (MLS) <5mm, GCS score>8, and no focal neurological deficit; 2. If the GCS score is ≥ 13, the imaging standards can be appropriately relaxed
Who cannot take part
- Patients who require craniotomy surgery to remove hematoma;
- There may be anatomical variations that may affect the safety of MMA embolization surgery and are not suitable for endovascular embolization;
- Having undergone major surgical procedures within 30 days before surgery;
- Combined intracranial tumors and other intracranial space occupying diseases;
- There are contraindications for cerebral angiography, such as iodine contrast agent allergy, embolization material allergy etc.;
- Severe comorbidities, may prevent improvement of the condition or completion of follow-up;
- Suffering from malignant tumors with an expected lifespan of less than 1 year;
- Coagulation dysfunction (preoperative INR>1.5), abnormal platelet count and function (platelet < 80×109/L);
- Bilateral acute epidural hematoma;
- Combined severe acute subdural hematoma;
- Brainstem injury;
- There are obvious brain contusions, lacerations, intracerebral hematomas, etc;
- Severe damage to combined extracranial organs;
- mRS score > 2 before injury;
- Currently participating in other clinical trials;
- Pregnant women;
- Unable to complete follow-up as required by the protocol;
- The physician believes that the patient has other circumstances that are not suitable for participation in this study
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
A prospective, multicenter, randomized controlled, open-label, blinded endpoint evaluation study.
The 2 groups in the trial
- Intervention groupTreatment being tested
MMA embolization
Treatment: MMA embolization plus medical therapy
- Control groupExisting treatment, for comparison
Conservative treatment
Treatment: Medical therapy alone
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 4 April 2025